前列腺导管内癌男性患者辅助放疗获益的回顾性研究
该回顾性研究纳入两个中心1993—2015年接受根治性前列腺切除术的pT2-T3期前列腺癌患者293例,比较术后辅助放疗与未放疗者的生化复发风险。中位随访99个月,48例(16.4%)接受辅助放疗。多因素分析显示IDC-P对生化复发影响最强(HR=2.39,95%CI 1.44-3.97),辅助放疗降低生化复发风险(HR=0.38,95%CI 0.17-0.85)。
要点
- IDC-P是生化复发最强影响因素,HR=2.39(95%CI 1.44-3.97)。
- 辅助放疗降低生化复发风险,HR=0.38(95%CI 0.17-0.85)。
- 未接受辅助放疗的IDC-P[+]患者无生化复发生存最差(log-rank P=0.023)。
核心结论
- 未接受辅助放疗的IDC-P患者生化复发率最高。
- IDC-P对无生化复发生存的影响与≥1项高危特征相同(log-rank P=0.955)。
- 作者认为,一旦得到验证,IDC-P患者应考虑辅助放疗。
研究设计与样本
- 回顾性研究,纳入两个中心1993—2015年接受根治性前列腺切除术的pT2-T3期前列腺癌男性患者。
- 共回顾293例根治性前列腺切除术标本,中位随访99个月,发生69例生化复发。
- 48例(16.4%)接受根治性前列腺切除术+辅助放疗。
- 排除标准为生化复发前接受其他类型治疗,以及根治性前列腺切除术后或辅助放疗后可检测到前列腺特异性抗原。
- 主要结局为生化复发,定义为连续2次前列腺特异性抗原≥0.2 ng/ml。
主要发现
- 多因素Cox回归显示,IDC-P对生化复发影响最强(HR=2.39,95%CI 1.44-3.97)。
- 辅助放疗降低生化复发风险(HR=0.38,95%CI 0.17-0.85)。
- 除pT3b期外,其他高危特征均显著。
- 未接受辅助放疗的IDC-P[+]患者无生化复发生存最差(log-rank P=0.023)。
- IDC-P对无生化复发生存的影响与≥1项高危特征相同(log-rank P=0.955)。
关键数值与推荐
- 高危特征定义为Grade Groups 4-5、切缘阳性、pT3期。
- 生化复发定义为连续2次前列腺特异性抗原≥0.2 ng/ml。
临床怎么用
- 作者认为,一旦得到验证,IDC-P患者应考虑辅助放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraductal carcinoma of the prostate (IDC-P) is an independent biomarker of recurrence and survival with particular treatment response, yet no study has tested its response to radiotherapy. The aim of our project was to test the impact of adjuvant radiotherapy (ART) in patients with localized to locally advanced prostate cancer (PC) and IDC-P. MATERIALS AND METHODS: We performed a retrospective study of men with pT2-T3 PC treated by radical prostatectomy (RP) with or without ART, from two centres (1993-2015). Exclusion criteria were the use of another type of treatment prior to biochemical recurrence (BCR), and detectable prostate- specific antigen (PSA) following RP or ART. Primary outcome was BCR (2 consecutive PSA ≥ 0.2 ng/ml). Patients were grouped by treatment (RPonly/RP + ART), IDC-P status, and presence of high-risk features (HRF: Grade Groups 4-5, positive margins, pT3 stage). RESULTS: We reviewed 293 RP specimens (median follow-up 99 months, 69 BCR). Forty-eight patients (16.4%) were treated by RP + ART. Multivariate Cox regression for BCR indicated that IDC-P had the strongest impact (hazard ratio [HR] = 2.39, 95% confidence interval [CI]:1.44-3.97), while ART reduced the risk of BCR (HR = 0.38, 95%CI: 0.17-0.85). Other HRF were all significant except for pT3b stage. IDC-P[+] patients who did not receive ART had the worst BCR-free survival (log-rank P = 0.023). Furthermore, IDC-P had the same impact on BCR-free survival as ≥1 HRF (log-rank P = 0.955). CONCLUSION: Men with IDC-P who did not receive ART had the highest BCR rates, and IDC-P had the same impact as ≥1 HRF, which are often used as ART indications. Once validated, ART should be considered in patients with IDC-P.
引用
- Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, et al. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiat Oncol. 2019. PMID: 31018850. doi:10.1186/s13014-019-1267-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。